Article: Biotech Holdings Sucanon drug facility on schedule for completion.

Robert Rieveley, President of Biotech Holdings (the "Company", TSX-VEN: BIO.V; OTCBB: BIOHF) announced that the Company is on schedule for completing work at its Sucanon drug production facility.

"We have acquired all of the pharmaceutic processing machinery and equipment necessary for the production of Sucanon active ingredients and are progressing as planned with installation and related work at our production facility. We are planning for the facility to be ready for production as of the end of March," Mr. Rieveley said.

"Inventory is now being ordered for production of the active ingredients for Sucanon, with Sucanon production being initiated in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!